Strs Ohio Grows Position in United Therapeutics Corporation $UTHR

Strs Ohio raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 68.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 27,614 shares of the biotechnology company’s stock after purchasing an additional 11,198 shares during the quarter. Strs Ohio’s holdings in United Therapeutics were worth $16,375,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Root Financial Partners LLC boosted its position in shares of United Therapeutics by 134.8% during the 1st quarter. Root Financial Partners LLC now owns 324 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 186 shares during the last quarter. IFM Investors Pty Ltd bought a new stake in United Therapeutics in the first quarter worth $5,264,000. Lansforsakringar Fondforvaltning AB publ raised its stake in United Therapeutics by 0.3% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 13,396 shares of the biotechnology company’s stock valued at $7,944,000 after purchasing an additional 39 shares in the last quarter. Apollon Wealth Management LLC purchased a new stake in United Therapeutics during the first quarter valued at $7,880,000. Finally, Janney Montgomery Scott LLC lifted its position in United Therapeutics by 2.1% during the first quarter. Janney Montgomery Scott LLC now owns 35,104 shares of the biotechnology company’s stock valued at $20,816,000 after purchasing an additional 735 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on UTHR shares. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $619.42.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,894,849.68. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 632,718 shares of company stock worth $356,533,651. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $555.91 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a market capitalization of $23.60 billion, a price-to-earnings ratio of 20.52, a PEG ratio of 1.82 and a beta of 0.58. The company has a fifty day moving average of $558.34 and a two-hundred day moving average of $527.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $6.63 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.